Lakefront Biotherapeutics (LKFT) Receivables - Net (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Receivables - Net for 13 consecutive years, with $24.7 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Net fell 57.5% year-over-year to $24.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.7 million (down 57.5% YoY) and the FY2025 annual result came in at $23.6 million, down 56.39% from the prior year.
• Receivables - Net climbed to $24.7 million in Q1 2026 per LKFT's latest filing, from $23.6 million in the prior quarter.
• Over the last five years, Receivables - Net for LKFT reached as high as $70.2 million in Q1 2022 and fell as low as $8.0 million in Q4 2024.
• A 5-year average of $45.6 million and a median of $51.6 million in 2025 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2024 — Receivables - Net sank 75.39% — and 2025, when it surged 195.8%.
• Year by year, Receivables - Net stood at $46.0 million in 2022, then declined by 29.63% to $32.4 million in 2023, then tumbled by 75.39% to $8.0 million in 2024, then jumped by 195.8% to $23.6 million in 2025, then gained by 4.98% to $24.7 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $24.7 million, $23.6 million, and $51.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.